Ultraflex stent placement.
The Oncology service was consulted to make a recommendation on the management, further work up, and treatment of her disease.
She uses a cane to walk at baseline; however, over the past month she has moved slower than usual with her cane.
Before transfer to OMED, the patient underwent: Rigid bronchoscopy, Flexible bronchoscopy, Endobronchial biopsy, Transbronchial needle aspiration, Balloon dilation, Ultraflex stent placement, Y-stent placement on [**2157-6-11**] by Dr. [**Last Name (STitle) **].
A flexible bronchoscopy was done on [**2157-6-13**] by Dr. [**Last Name (STitle) **] to assess the patency of airway stents and for therapeutic suctioning of secretions.
Both silicone Y-stent as well as the left mainstem metallic stent appeared patent as well as patency of distal airways in both right and the left bronchial trees.
Pertinent Results: LABS ON ADMISSION: [**2157-6-10**] 05:57PM BLOOD WBC-7.7 RBC-4.28 Hgb-12.5 Hct-38.3 MCV-90 MCH-29.2 MCHC-32.7 RDW-13.6 Plt Ct-283 [**2157-6-10**] 05:57PM BLOOD PT-13.5* PTT-27.6 INR(PT)-1.2* [**2157-6-10**] 05:57PM BLOOD Glucose-140* UreaN-17 Creat-1.1 Na-141 K-3.4 Cl-101 HCO3-29 AnGap-14 [**2157-6-10**] 05:57PM BLOOD Calcium-9.6 Phos-3.6 Mg-1.8 [**2157-6-10**] 10:30PM BLOOD Type-ART pO2-33* pCO2-53* pH-7.39 calTCO2-33* Base XS-5 [**2157-6-18**] 12:33PM URINE Blood-MOD Nitrite-NEG Protein-TR Glucose-NEG Ketone-NEG Bilirub-NEG Urobiln-NEG pH-5.0 Leuks-LG [**2157-6-18**] 12:33PM URINE RBC-38* WBC-122* Bacteri-FEW Yeast-MANY Epi-10 TransE-2 [**2157-6-18**] 12:33PM URINE CastGr-6* CastHy-6*  LABS ON DISCHARGE: [**2157-6-22**] 06:35AM BLOOD WBC-6.9 RBC-3.93* Hgb-11.4* Hct-34.6* MCV-88 MCH-29.0 MCHC-33.0 RDW-13.6 Plt Ct-244 [**2157-6-18**] 06:55AM BLOOD Neuts-87.6* Lymphs-8.6* Monos-3.3 Eos-0.2 Baso-0.3 [**2157-6-22**] 06:35AM BLOOD Plt Ct-244 [**2157-6-20**] 06:00AM BLOOD Glucose-172* UreaN-31* Creat-1.0 Na-139 K-4.1 Cl-104 HCO3-27 AnGap-12 [**2157-6-19**] 06:30AM BLOOD CK(CPK)-24* [**2157-6-20**] 06:00AM BLOOD Calcium-9.2 Phos-3.0 Mg-1.8 UricAcd-3.7  MICROBIOLOGY: [**2157-6-18**]	BLOOD CULTURE - No Growth [**2157-6-18**]	URINE	URINE CULTURE-FINAL {YEAST} [**2157-6-16**]	STOOL	CLOSTRIDIUM DIFFICILE TOXIN A & B Negative [**2157-6-13**]	BLOOD  CULTURE ( MYCO/F LYTIC BOTTLE)	BLOOD/FUNGAL CULTURE-FINAL; BLOOD/AFB CULTURE-FINAL	INPATIENT [**2157-6-11**]	TISSUE	GRAM STAIN-FINAL; TISSUE-FINAL {VIRIDANS STREPTOCOCCI, VIRIDANS STREPTOCOCCI}; ANAEROBIC CULTURE-FINAL; ACID FAST SMEAR-FINAL; ACID FAST CULTURE-PRELIMINARY; FUNGAL CULTURE-FINAL  [**2157-6-11**] TISSUE      TRANSBRONCHIAL BRONCHIAL NEEDLE ASPIRATE.
But significant intramural plaque in the descending aorta with mural calcification.
Cultures Neg To Date: [**2157-6-18**] BLOOD CULTURE Blood Culture, Routine-PENDING INPATIENT [**2157-6-18**] URINE URINE CULTURE-FINAL {YEAST} INPATIENT [**2157-6-16**] STOOL CLOSTRIDIUM DIFFICILE TOXIN A & B TEST-FINAL INPATIENT [**2157-6-14**] STOOL CLOSTRIDIUM DIFFICILE TOXIN A & B TEST-FINAL INPATIENT [**2157-6-13**] BLOOD CULTURE ( MYCO/F LYTIC BOTTLE) BLOOD/FUNGAL CULTURE-PRELIMINARY; BLOOD/AFB CULTURE-PRELIMINARY INPATIENT .
She was placed on Heliox 3L Nasal cannula with good Sa)2 99% and standing nebs.
Ultraflex stent placement and Y-stent placement.
She was transferred to the SICU following the procedure for airway monitoring.
On [**2157-6-13**] she had flexible bronchoscopy to evaluate Y stent placement and therapeutic aspiration of secretions.
Extensive stage disease given disease cannot be confined to one radiation port, she has diffuse bony mets on MR [**Name13 (STitle) **] (no cord compression) although her brain MR did not show any mets despite study limited by motion artifact.
It was determined that she would receive [**Doctor Last Name **]/etoposide with tumor lysis ppx consisting of allopurinol 300 daily.
[**Last Name (un) **] beginning chemo the pt had UOP < 30cc which responded well to continuous IVF 100cc/hr NS and 500 cc bolus.
Leukocytosis: Afebrile, but WBC up to 14, probably secondary to decadron concurrent with chemo.
The patient was not placed on antibiotics and monitored clinically as she was asymptomatic.
Patient has PMH of peripheral neuropathy, probable [**1-10**] DM although distribution unorthodox given no foot neuropathy.
CK was 24 so not thought to be due to statin myalgia.
DM: Held home metformin to avoid nephrotox since starting chemo.
Insulin sliding scale was increased as patient takes decadron as part of chemo.
Medications on Admission: Cardizem 240 qd,  Glucophage 1000 mg [**Hospital1 **], Vasotec 20 mg daily, Zocor 40 mg daily, Triamterene-HCTZ 37.5/25 mg daily, Detrol 4mg daily, Duonebs Flovent 110 mcg daily  Discharge Medications: 1.
Heparin (Porcine) 5,000 unit/mL Solution Sig: One (1) Injection TID (3 times a day).
Diltiazem HCl 30 mg Tablet Sig: Two (2) Tablet PO QID (4 times a day).
Famotidine 20 mg Tablet Sig: One (1) Tablet PO BID (2 times a day).
Ipratropium Bromide 0.02 % Solution Sig: One (1)  Inhalation Q6H (every 6 hours).
Simvastatin 10 mg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Enalapril Maleate 5 mg Tablet Sig: Four (4) Tablet PO DAILY (Daily).
Hydrochlorothiazide 12.5 mg Capsule Sig: One (1) Capsule PO DAILY (Daily).
Guaifenesin 100 mg/5 mL Syrup Sig: Ten (10) ML PO Q6H (every 6 hours).
Codeine-Guaifenesin 10-100 mg/5 mL Syrup Sig: Five (5) ML PO Q6H (every 6 hours) as needed for cough.
Oxycodone-Acetaminophen 5-325 mg Tablet Sig: One (1) Tablet PO Q4H (every 4 hours) as needed for pain.
Prochlorperazine Maleate 10 mg Tablet Sig: One (1) Tablet PO Q6H (every 6 hours) as needed for nausea.
Acetylcysteine 20 % (200 mg/mL) Solution Sig: One (1) ML Miscellaneous Q 8H (Every 8 Hours): Stent care.
Benzonatate 100 mg Capsule Sig: One (1) Capsule PO TID (3 times a day) as needed for phlegm.
Albuterol Sulfate 2.5 mg /3 mL (0.083 %) Solution for Nebulization Sig: One (1)  Inhalation Q4H (every 4 hours) as needed for copd.
Albuterol Sulfate 2.5 mg /3 mL (0.083 %) Solution for Nebulization Sig: One (1)  Inhalation Q 8H (Every 8 Hours).
A stent was placed in your lung to help your breathing.
You also received one cycle of chemotherapy (Carboplatin, Etoposide) and have been arranged to follow-up with an oncologist at [**Hospital3 **].
A list of medications has been provided to your rehab.
For pulmonary follow-up call Dr. [**Last Name (STitle) **], ([**Telephone/Fax (1) 17398**] regarding your stent placement.
